European Journal of Pharmaceutical Sciences is the official journal of the European Federation for Pharmaceutical Sciences (EUFEPS).

The journal publishes research articles, review articles, perspectives and scientific commentaries on all aspects of the pharmaceutical sciences with emphasis on conceptual novelty and scientific quality. The Editors welcome articles in this multidisciplinary field, with a focus on topics relevant for drug discovery and drug development.

More specifically, the European Journal of Pharmaceutical Sciences publishes reports on:
drug absorption and metabolism,
drug delivery including nucleic acid delivery,
drug evaluation in the clinic,
drug targeting,
medicinal chemistry,
personalised and precision medicine,
pharmaceutical and biomedical analysis,
pharmaceutical biotechnology,
pharmaceutical technology and manufacturing,
pharmacodynamics,
pharmacokinetics,
pharmacology including translational pharmacology,
physical chemistry related to formulation, physical pharmacy and preformulation,
regulatory science.
New chemical entities, new biological entities, prodrugs, peptides and new modalities such as antibody-drug-conjugates (ADCs), PROTACs, advanced therapy medicinal products (ATMPs) including nucleic acid modalities (e.g., siRNA or mRNA), cell-based therapies are within the scope of the journal.

Manuscripts describing new technical aspects such as new methods, new routes of synthesis, new formulation approaches, applied engineering, nanotechnology or the use of in silico tools for modelling and pharmaceutical data science are welcome.

European Journal of Pharmaceutical Sciences publishes contributions dealing with relevant aspects of pediatrics, treatment of elderly patients e.g., impaired pharmacokinetics. Manuscripts covering rare diseases, are also within the scope of the journal.

The journal will typically not give priority to manuscripts focusing exclusively on organic synthesis of bioactive small molecules and adaptation of analytical approaches, unless they prove to be of key importance in the drug discovery and development process. Topics or discussions pertaining to drug policy making do not have priority. In silico studies, such as molecular modelling, bulk scale modelling and virtual screening, unless reporting novel and broadly applicable methods, can be considered only if supported by experimental studies and verification of the pharmaceutical relevance of modelling results. Homeopathic medicines, phytochemical and pharmacological studies on plant extracts, traditional Chinese medicines and of isolated drug compounds of natural origin are not in the focus for European Journal of Pharmaceutical Sciences.

Review articles, perspectives and scientific commentaries are generally by invitation or by consent of the Editors. Proceedings of scientific meetings may be published as special issues upon discussions with the Editor/Publisher.

Research articles
Review articles
Commentaries and Mini-reviews
Commentaries (Guidance)
Mini-review (Guidance)

Editor-in-Chief
Martin Brandl
Dept. of Physics, Chemistry and Pharmacy, University of Southern Denmark, Campusvej 55, DK-5230, Odense M, Denmark Email Martin Brandl
Section Editors
Cosimo Altomare
Università degli Studi di Bari Aldo Moro, Bari, Italy
Carsten Ehrhardt
Trinity College Dublin, Dublin, Ireland
Jelena Filipović-Grčić
Sveučilišta u Zagrebu, Zagreb, Croatia
Jukka Rantanen
University of Copenhagen, Copenhagen, Denmark
Christoph Ritter
University of Greifswald, Greifswald, Germany
Christoph Saal
Merck KGaA, Darmstadt, Germany
Bruno Sarmento
Universidade do Porto, Porto, Portugal
Stephan Schmidt
University of Florida, Orlando, Florida, USA
Nataša Škalko-Basnet
Universitetet i Tromsø, Tromsø, Norway
Guy Van den Mooter
KU Leuven, Leuven, Belgium
Joan Zuo
The Chinese University of Hong Kong, Shatin, N.T., Hong Kong
Editorial Board
L.J. Aarons
University of Manchester, Manchester, UK
F. Ahsan
Texas Tech School of Pharmacy, Amarillo, Texas, USA
J.M. Aiache
University of Clermont-Ferrand, Clermont-Ferrand, France
M.J. Alonso
Universidade de Santiago de Compostela, Santiago de Compostela, Spain
P. Artursson
Uppsala Universitet, Uppsala, Sweden
B. Aungst
AUC Sciences, Newark, Delaware, USA
S. Auriola
University of Eastern Finland, Kuopio, Finland
A. Avdeef
in-ADME Research, New York, New York, USA
M. Bermejo Sanz
Universidad Miguel Hernández (UMH), San Juan de Alicante, Spain
O.J. Bjerrum
University of Copenhagen, Copenhagen, Denmark
H.H. Blume
Socratec R&D, Oberursel, Germany
J.A. Bouwstra
Leiden/Amsterdam Center for Drug Research (LACDR), Leiden, Netherlands
D. Brayden
University College Dublin, Dublin, Ireland
C. Caramella
Università degli Studi di Pavia, Pavia, Italy
A. Dahan
Ben-Gurion University of the Negev, Israel
M. Davies
The University of Nottingham, Nottingham, UK
S.C. De Smedt
Universiteit Gent, Gent, Belgium
H. Derendorf
University of Florida, Gainesville, Florida, USA
M. Eichelbaum
Dr. Margarete Fischer-Bosch Inst., Stuttgart, Germany
A. Fahr
Friedrich-Schiller-Universität Jena, Jena, Germany
M. Finel
University of Helsinki, Helsinki, Finland
S.Y.K Fong
University of Southern Denmark, Odense, Denmark
G. Fricker
Institut für Pharmazie und Molekulare Biotechnologie, Heidelberg, Germany
H. W. Frijlink
Rijksuniversiteit Groningen, Groningen, Netherlands
G. Garbacz
Physiolution GmbH, Greifswald, Germany
G. Golomb
Hebrew University of Jerusalem, Jerusalem, Israel
R.H. Guy
University of Bath, Bath, UK
J. Hirvonen
University of Helsinki, Helsinki, Finland
R. Holm
Lundbeck Copenhagen
P. Honkakoski
University of Eastern Finland, Kuopio, Finland
L. Illum
IDentity / Cosmas-Damian Ltd., Nottingham, UK
G. Imanidis
Universität Basel, Basel, Switzerland
K.-I. Inui
Kyoto Pharmaceutical University, Kyoto, Japan
H.E. Junginger
M.O. Karlsson
Uppsala Universitet, Uppsala, Sweden
J. Kopecek
University of Utah, Salt Lake City, UT, USA
R. Kostiainen
University of Helsinki, Helsinki, Finland
R. Langer
Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
C.-M. Lehr
Helmholtz-Institute for Pharmaceutical Research and Saarland University, Saarbrücken, Germany
H. Lennernäs
Uppsala Universitet, Uppsala, Sweden
P. Macheras
University of Athens, Athens, Greece
U. Massing
KTB Klinik für Tumorbiologie, Freiburg, Germany
C. Middaugh
University of Kansas, Lawrence, Kansas, USA
S. Mitragotri, MS, PhD
Harvard University, Cambridge, Massachusetts, USA
C. O'Driscoll
University College Cork, Cork, Ireland
O. Pelkonen
University of Oulu, Oulu, Finland
G. Perlovich
Russian Academy of Sciences, Ivanovo, Russian Federation
J.E. Polli
University of Maryland, Baltimore, Maryland, USA
J.P. Remon
Universiteit Gent, Ghent, Belgium
J.S. Remy
Université de Strasbourg, Illkirch, France
R.C. Rowe
University of Bradford, Bradford, West Yorkshire, UK
W. Sadée
The Ohio State University, Columbus, Ohio, USA
E.H. Schacht
Universiteit Gent, Gent, Belgium
J. Siepmann
Université de Lille, Lille, France
E. B. Souto
Universidade de Coimbra, Coimbra, Portugal
S. Spampinato
Università di Bologna, Bologna, Italy
G. Storm
Universiteit Utrecht, Utrecht, Netherlands
Y. Sugiyama
The University of Tokyo, Tokyo, Japan
Y. Takakura
Kyoto University, Kyoto, Japan
G.T. Tucker
University of Sheffield, Sheffield, UK
K. Uekama
Kumamoto University, Kumamoto, Japan
K. Ulbrich
Academy of Sciences of the Czech Republic, Prague, Czech Republic
A. Urtti
University of Helsinki, Helsinki, Finland
H. van de Waterbeemd
Saint Andre, France
M.R. Vert
Université de Montpellier, Montpellier, France
S. Visser
Merck Research Laboratories, North Wales, Pennsylvania, USA
E. Wagner
Ludwig-Maximilians-Universität München (LMU), München, Germany
M. Yliperttula
University of Helsinki, Helsinki, Finland